ResMed Inc. found using ticker (RMD) now have 6 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 276 and 222 with the average target price sitting at 253.33. With the stocks previous close at 213.69 this is indicating there is a potential upside of 18.6%. The day 50 moving average is 230.48 and the 200 day moving average is 230.45. The market cap for the company is $31,410m. Visit the company website at: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets="RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $37,236m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
→ Google 번역
New Jersey, NJ -- ( SBWIRE ) -- 09/07/2022 -- The Latest research study released by HTF MI "Global and Regional Life Support Systems Market" with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Some of the Major Companies covered in this Research are Philips, ZOLL Medical, Stryker, Physio-Control, LivaNova, Medtronic, BD, Abbott Laboratories, Cardiac Science, Nihon Kohden, Schiller, Resmed, GE Healthcare, Fisher & Paykel, Drager Medical, A.M.I. Italia, Metrax GmbH, Instramed, METsis Medikal, Mindray, Promed Group, eVent Medical, Allied Healthcare Products, Beijing M&B Electronic & Shenzhen XFT etc. Click here for free sample + related graphs of the report @: https://www.htfmarketreport.com/sample-report/4147174-2022-2027-global-and-regional-life-support-systems-industry-status-and-prospects-professional-market Browse market information, tables and figures extent in-depth TOC on "Life Support Systems Market by Application (Hospitals, Clinics & Ambulatory Surgical Centers), by Product Type (Automated External Defibrillator, Extracorporeal Oxygenator, Ventilator & Others), Business scope, Manufacturing and Outlook – Estimate to 2027". for more information or any query mail at sales@htfmarketreport.com At last, all parts of the Global and Regional Life Support Systems Market are quantitatively also subjectively valued to think about the Global just as regional market equally.
→ Google 번역
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the 20 th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, beginning at approximately 8:45 a.m. (Eastern Daylight Time) at the Sheraton New York in New York City.
→ Google 번역
ResMed continues to offer long-term compelling value through a strengthening earnings profile and double-digit return on investment. See why RMD stock is a buy.
→ Google 번역
ResMed has done well to grow its top and bottom lines recently, but this doesn''t make the company a great investment prospect. Read more about RMD stock here.
→ Google 번역
https://www.investing.com/news/pro/clsa-downgrades-resmed-rmdau-to-outperform-2-high-nearterm-expectations-may-detract-from-longterm-tailwinds-432SI-2872386
→ Google 번역
https://www.investing.com/news/pro/macquarie-reiterates-outperform-rating-on-resmed-432SI-2872002
→ Google 번역
ResMed Inc. with ticker code (RMD) have now 6 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 276 and 204 with the average target price sitting at 244.33. With the stocks previous close at 240.85 this would indicate that there is a potential upside of 1.4%. There is a 50 day moving average of 221.22 and the 200 day MA is 235.33. The company has a market cap of $35,505m. Visit the company website at: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets="RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,018m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
→ Google 번역
ResMed Inc (NYSE: RMD ) posted Q4 sales of $914.7 million , +4% Y/Y (+8% on a constant currency basis), beating the consensus of $912.97 million. Adjusted EPS reached $1.49, up from $1.35 a year ago. The company also increased its quarterly dividend to $0.44 from $0.42 per share. Keybanc reiterates the Overweight rating and price target of $276. The analyst says that after resetting near-term supply chain expectations, visibility appears to … Full story available on Benzinga.com
→ Google 번역
ResMed (RMD) traded lower Friday despite posting better than expected financials for Q4 fiscal 2022 after JPMorgan and RBC Capital Markets moved to downgrade the dual-listed…
→ Google 번역
Tuesday marks the last chance for investors to receive the next dividend payout from ResMed (NYSE: RMD ). What''s Happening The company announced on Thursday that it would pay shareholders a quarterly dividend of 44 per share. On Wednesday, ResMed will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, … Full story available on Benzinga.com
→ Google 번역
https://www.investing.com/news/pro/jpmorgan-downgrades-resmed-to-neutral-432SI-2871436
→ Google 번역
Australian shares are set to open modestly lower. Reporting today: Baby Bunting, IAG, ResMed. Wall St debates US rate outlook. Follow updates here.
→ Google 번역
ResMed press release (RMD): Q4 Non-GAAP EPS of $1.49 beats by $0.03.Revenue of $914.74M (+4.4% Y/Y) beats by $2.22M.Non-GAAP gross margin grew 50 bps to 57.8%, non-GAAP operating…
→ Google 번역
(PLX AI) – ResMed Q4 revenue USD 914.7 million vs. estimate USD 921 million.Q4 gross margin 57.1%Q4 adjusted gross margin 57.8%Q4 adjusted EPS USD 1.49Q4 EPS USD 1.33Says confident in our ability to grow steadily throughout fiscal year 2023 and to …
→ Google 번역
DIS, ILMN, AIG, TDG, SYY, D, EMR, WELL, RMD, and IFF all have company earnings announcements this week. This summary looks back at their… Continue reading on Databyte Financial Insights »
→ Google 번역
ResMed Inc. with ticker code (RMD) now have 6 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 276 and 204 and has a mean target at 244.33. Now with the previous closing price of 238.7 this indicates there is a potential upside of 2.4%. There is a 50 day moving average of 217.5 while the 200 day moving average is 235.98. The company has a market capitalisation of $35,372m. You can visit the company''s website by visiting: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets="RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,206m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
→ Google 번역
ResMed''s (NYSE: RMD ) short percent of float has risen 14.44% since its last report. The company recently reported that it has 1.50 million shares sold short , which is 1.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
→ Google 번역
This year has been a particularly rough year for growth stocks. The severe macroeconomic climate has led to a broad risk-off investment sentiment, forcing investors toward defensive plays. On the positive side, there are plenty of opportunities to buy well-known growth names at discounted valuations. For example, the Vanguard Growth ETF (NYSEARCA: VUG ), one of the largest growth exchange-traded funds (ETFs), is down 31% year-to-date (YTD), compared to a 21% decline for the S&P 500 index. Meanwhile, the iShares Russell 1000 Growth ETF (NYSEARCA: IWF ) has declined 28% in 2022, twice the 14% dip for its counterpart, the iShares Russell 1000 Value ETF (NYSEARCA: IWD ). The 7 Worst Stocks to Buy in a Bear Market However, history tells us high-growth stocks constitute a smart place for long-term investors to allocate a portion of their investment portfolio. With that information, here are seven growth stocks for Q3. Ticker Company Current Price ADI Analog Devices $145 NET Cloudflare $42.71 FAST Fastenal $49.77 LRCX Lam Research $421.50 RMD Resmed $211.55 SHOP Shopify $31.52 TER Teradyne $89.19 Analog Devices (ADI) Semiconductor play Analog Devices (NASDAQ: ADI ) manufactures integrated circuits that process high-performance analog and digital signals.
→ Google 번역
Hub24 and ResMed are among this broker''s favourites. The post Broker rates these 2 top ASX 200 shares as buys in July appeared first on The Motley Fool Australia .
→ Google 번역
Major players in the positive airway pressure devices market are ResMed Inc, Koninklijke Philips N. V, 3B Medical Inc, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, Somnetics International Inc, Heyer Medical, Genstar Technologies, BMC Medical, and Apex Medical. Major players in the positive airway pressure devices market are ResMed Inc, Koninklijke Philips N. V, 3B Medical Inc, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, Somnetics International Inc, Heyer Medical, Genstar Technologies, BMC Medical, and Apex Medical.
→ Google 번역
Major players in the respiratory devices and equipment market are Smiths Medical, Philips Healthcare, GE Healthcare, Chart Industries, Invacare Corporation, Fisher & Paykel Healthcare Limited, ResMed, Dragerwerk AG, Medtronic plc, Masimo corp. Major players in the respiratory devices and equipment market are Smiths Medical, Philips Healthcare, GE Healthcare, Chart Industries, Invacare Corporation, Fisher & Paykel Healthcare Limited, ResMed, Dragerwerk AG, Medtronic plc, Masimo corp.
→ Google 번역
Major players in the respiratory disposables market are Fisher & Paykel, Becton Dickinson Company, Ambu A/S, Smiths Medical, Armstrong Medical, Teleflex, Philips Respironics, Besmed, ResMed, and Dynarex. Major players in the respiratory disposables market are Fisher & Paykel, Becton Dickinson Company, Ambu A/S, Smiths Medical, Armstrong Medical, Teleflex, Philips Respironics, Besmed, ResMed, and Dynarex.
→ Google 번역
ResMed Inc''s (NYSE: RMD ) Q3 FY22 sales increased by 12% Y/Y (+14% on a constant currency basis) to $864.5 million, missing the consensus of $897 million. The revenue growth was driven by increased demand for sleep and respiratory care devices and an increased demand following an ongoing recall of rival Koninklijke Philips N.V. (NYSE: PHG ) products. ResMed generated $35 … Full story available on Benzinga.com
→ Google 번역
HOUSTON, April 27, 2022 (GLOBE NEWSWIRE) -- Carriage Services, Inc. (NYSE: CSV ): today announced results for the first quarter ended March 31, 2022. Record Quarterly Revenue of $98.2 million, GAAP Diluted EPS of $1.00 and Adjusted Diluted EPS of $0.92; Invested $168.5 million since May 13, 2021 to repurchase 3.4 million shares (19% of outstanding) at $49.60 per share; Capital Allocation now focused on internal growth (mostly cemetery property development) and high quality acquisitions; Updated Rolling Four Quarter Outlook and Three Year Roughly Right Ranges Performance Scenario Through 2024; Discretionary Trust Fund Positive Total Return of 4.3%; and Management''s Opinion of Intrinsic Value Roughly Right Range remains at $70 to $80 per share. Mel Payne, Chairman and CEO, stated, "I highly recommend that anyone interested in Carriage for any reason read my most recent 2021 Shareholder Letter, co-written by the three other members of our Strategic Vision and Principles Group (SVPG), Carlos Quezada, Ben Brink and Steve Metzger, together with our Proxy Statement for our Annual Meeting of stockholders on May 17, 2022.
→ Google 번역
Strong EPS growth and margin expansion driven by Commercial Aerospace WALTHAM, Mass. , April 26, 2022 /PRNewswire/ -- Raytheon Technologies Corporation (NYSE: RTX ) reported first quarter 2022 results and updated its 2022 outlook. First quarter 2022 Sales of $15.7 billion , up 3 percent versus prior year including 4 percent organic growth GAAP EPS from continuing operations of $0.74 , up 45 percent versus prior year, including $0.41 of acquisition accounting adjustments and net significant and/or non-recurring charges Adjusted EPS of $1.15 , up 28 percent versus prior year Operating cash flow from continuing operations of $476 million ; Free cash flow of $37 million Achieved approximately $90 million of incremental RTX gross cost synergies Repurchased $743 million of RTX shares Outlook for full year 2022 Sales of $67.75 - $68.75 billion , down from $68.5 - $69.5 billion . Driven by global sanctions on Russia . Confirms adjusted EPS of $4.60 - $4.80 Confirms free cash flow of approximately $6.0 billion .
→ Google 번역
NEW YORK , April 7, 2022 /PRNewswire/ -- According to the research report, Portable Oxygen Concentrators Market will witness a YOY growth of 8.8% in 2022 at a CAGR of 12.52% during the forecast period. The report is segmented by product (pulse dose and continuous flow) and geography ( North America , Europe , Asia , and Rest of World (ROW)). The rising frequency of respiratory illnesses is one of the major reasons driving the worldwide portable oxygen concentrators market. For more insights on YOY and CAGR, Read our FREE Sample Report Vendor Insights Portable Oxygen Concentrators Market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Some vendors are also adopting inorganic growth strategies such as M&As to remain competitive in the market.
→ Google 번역
SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 32 nd Annual Healthcare Conference on Tuesday, March 15, 2022, beginning at approximately 1:20 p.m. (Eastern Daylight Time) via webcast.
→ Google 번역
This report studies the Portable Breathing Machine Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Portable Breathing Machine market segmented by company, []
→ Google 번역
The report on Global Medical Oxygen Therapy Devices Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a []
→ Google 번역
The report on Global Portable Mechanical Ventil Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []
→ Google 번역
The report on Global CPAP Systems Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
→ Google 번역
The report on Global Invasive Ventilators Sales Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []
→ Google 번역
The report on Global Respiratory Devices Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
→ Google 번역
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (NASDAQ: TECH ) BioNTech SE (NASDAQ: BNTX ) (announced a collaboration with Biovac to manufacture COVID-19 shots in South Africa) Bristol-Myers Squibb Company (NYSE: BMY ) Cassava Sciences, Inc. (NASDAQ: SAVA ) Century Therapeutics, Inc. (NASDAQ: IPSC ) Cortexyme, Inc. (NASDAQ: CRTX ) (announced positive data for pipeline asset in periodontal disease) Eli Lilly and Company (NYSE: LLY ) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Legend Biotech Corporation (NASDAQ: LEGN ) NeuroMetrix, Inc. (NASDAQ: NURO ) (reacted to its second-quarter results) Novo Nordisk A/S (NYSE: NVO ) PLx Pharma Inc. (NASDAQ: PLXP ) ResMed Inc. (NYSE: RMD ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) 23andMe Holding Co.
→ Google 번역
This report studies the Snoring Control Devices Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Snoring Control Devices market segmented by company, []
→ Google 번역
This report studies the Nasal Masks Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Nasal Masks market segmented by company, region, type []
→ Google 번역
This report studies the Medical Noninvasive Ventilators Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Medical Noninvasive Ventilators market segmented by company, []
→ Google 번역
This report studies the Actigraphy Sensors and Polysomnography Devices Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Actigraphy Sensors and Polysomnography Devices []
→ Google 번역
Prescription Digital Therapeutics Dtx Market report has been prepared by effectively using technology, new applications, and expertise to manage large and complex market data tables and forecast automatically. The report endows precise and exact market research information including sound facts
→ Google 번역
Related Stocks: SCHZ , VNQ , SCHP , SCHR , VDC , JKH , MAR , RMD , UPS , DCI , NKE , TGT , IEFA , GE ,
→ Google 번역
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
→ Google 번역
The Breathing Mask Market report is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection from
→ Google 번역
The report titled Global Non-Invasive Breathing Systems Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Non-Invasive Breathing Systems market. The market analysts authoring this report have provided in-depth information on leading growth []
→ Google 번역
Resmed Inc. (RMD) shares closed today at 0.4% below its 52 week high of $254.21, giving the company a market cap of $36B. The stock is currently up 19.6% year-to-date, up 30.3% over the past 12 months, and up 318.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 37.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 48.7% The company's stock price performance over the past 12 months beats the peer average by 140.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -511.7% higher than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google 번역
Related Stocks: RMD ,
→ Google 번역
Resmed Inc. (RMD) shares closed today at 0.4% below its 52 week high of $254.21, giving the company a market cap of $36B. The stock is currently up 19.6% year-to-date, up 28.2% over the past 12 months, and up 318.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 29.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 48.7% The company's stock price performance over the past 12 months beats the peer average by 163.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -511.7% higher than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google 번역
Related Stocks: IGSB , ESGU , GOVT , DBX , FITB , TSLA , SQ , EPAM , EXPD , FALN , MED , NFLX , QCOM , CRM , DOCU , ETSY , RMD ,
→ Google 번역
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2021 on Thursday, August 5, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.
→ Google 번역
Related Stocks: RMD ,
→ Google 번역